Publication:
Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease

Simple item page
dc.contributor.authorChutintorn Sriphrapradangen_US
dc.contributor.otherFaculty of Medicine Ramathibodi Hospital, Mahidol Universityen_US
dc.date.accessioned2022-08-04T08:04:45Z
dc.date.available2022-08-04T08:04:45Z
dc.date.issued2021-11-01en_US
dc.identifier.citationEndocrine. Vol.74, No.2 (2021), 226-227en_US
dc.identifier.doi10.1007/s12020-021-02879-8en_US
dc.identifier.issn15590100en_US
dc.identifier.issn1355008Xen_US
dc.identifier.other2-s2.0-85115108725en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/75987
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85115108725&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleAggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ diseaseen_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85115108725&origin=inwarden_US

Files

Collections

Scopus 2021